Maxensia owor
ID: UNCST-2021-R014003
|
IMPAACT 2036: Phase I/II Study of the Safety, Tolerability, Acceptability, and Pharmacokinetics of Oral and Long-Acting Injectable Cabotegravir and Rilpivirine in Virologically Suppressed Children Living with HIV-1, Two to Less Than 12 Years of Age. Version 1.0, 22 September 2022. DAIDS study protocol ID: 38932
REFNo: HS2599ES
iii. Cohort 2: To describe the maintenance of viral suppression and immunologic activity of 48 weeks of CAB + RPV (oral and injectable) or 44 weeks of CAB LA + RPV LA (injectable only),iv. Cohort 2: To describe HIV-1 genotypes and phenotypes for children who experience virologic failure during 48 weeks of CAB + RPV (oral and injectable) or during 44 weeks of CAB LA + RPV LA (injectable only),ii. Cohort Cohort 2: To describe the safety and repeat-dose pharmacokinetics of 48 weeks of CAB + RPV (oral and injectable) or 44 weeks of CAB LA + RPV LA (injectable only),i. Cohort 2: To describe tolerability and acceptability of 48 weeks of CAB + RPV (oral and injectable) and 44 weeks of CAB LA + RPV LA (injectable only),ii Cohort 1: To assess the safety of the oral lead-in of CAB + RPV, and the safety of CAB + RPV (oral and injectable) through Week 24,i.Cohort 1: To describe the repeat-dose pharmacokinetics of CAB + RPV (oral and injectable) through Week 24,
|
Uganda |
2023-02-13 11:10:13 |
2026-02-13 |
Medical and Health Sciences |
Clinical Trial |
Non-degree Award |
|
Josphat Muchangi Martin
ID: UNCST-2022-R010507
|
Impact of the intervention ‘Financial Inclusion Improves Sanitation and Health 2022-2024’. A randomized controlled trial in Kenya and Uganda
REFNo: SS1587ES
To determine the cost-effectiveness of the FINISH model (creating earning opportunities, job market participation) and amount of leverage funds generated. ,To explore the perspectives, attitudes, and practices of various stakeholders (communities, governments, entrepreneurs, and financiers) regarding the FINISH model.,To estimate the impact of the FINISH model on health (diarrhoea occurrence, hygienic behaviour) and social (school attendance, sanitation) outcomes. ,To evaluate the impacts of the FINISH interventions in Kenya and Uganda.,
|
Kenya |
2023-02-13 11:06:11 |
2026-02-13 |
Social Science and Humanities |
Non-Clinical Trial |
Non-degree Award |
|
Denis Bwayo
ID:
|
Risk factors, genetics and mortality among patients with dilated cardiomyopathy in Uganda
REFNo: HS2444ES
1. To investigate risk factors, genetics, and moratlity among patients diagnosed with DCM in Uganda Delete
2.To determine the underlying genetics and inheritance characteristics of DCM in Uganda Delete
3. To determine the incidence and predictors of all-cause mortality 12 months after DCM diagnosis in Uganda
|
Uganda |
2023-02-13 11:04:24 |
2026-02-13 |
Medical and Health Sciences |
Non-Clinical Trial |
Degree Award |
|
Victoria Nankabirwa
ID: UNCST-2021-R011871
|
Use of the Global Scale for Early Development (GSED) within Preventing Infant Malnutrition with Early Supplementation (PRIMES) Trial
REFNo: HS2263ES
1) To obtain preliminary estimates of the correlation between Global Scale for Early Development (GSED) scores and MRI findings (total brain and white matter volumes) in infants at 6 and 12 months of age.
2) To assess user feedback about the Hyperfine LF MRI device.
3) To determine whether the Hyperfine LF MRI device is feasible and acceptable among healthcare personnel and caregivers of infants undergoing LF MRI.
|
Uganda |
2023-02-13 11:01:02 |
2026-02-13 |
Medical and Health Sciences |
Non-Clinical Trial |
Non-degree Award |
.jpg)
|
Winnie Muyindike R
ID: UNCST-2021-R013558
|
A Randomized Clinical Trial to Evaluate Solutions for the Management of Virologic Failure for Individuals on TLD in Sub-Saharan Africa.(RESOLVE)
REFNo: HS2620ES
Aim 2: Use simulation modeling to examine the clinical impact, costs, and cost-effectiveness of strategies to improve viral suppression after virologic failure on TLD. We will populate the previously validated Cost-Effectiveness of Preventing AIDS Complications-International (CEPAC-I) model with the novel clinical trial data from Aim 1 to project long-term clinical outcomes and cumulative lifetime costs. We will then compare the cost-effectiveness of the three strategies evaluated in Aim 1 for addressing virologic failure among people treated with first-line TLD in Uganda or South Africa. ,Aim 1: Conduct a randomized clinical trial to determine the optimal strategy for management of virologic failure on first-line TLD in SSA. We will recruit 648 adolescents and adults with two viral loads >1,000 copies/mL while on first-line TLD for at least 12 months, who are in care at one of six public-sector HIV clinics in Uganda or South Africa. We will randomize participants to one of the following strategies, stratified by clinic and prior NNRTI-exposure: a) Maintenance on TLD with switch to protease inhibitor (PI)-based second-line ART if virologic failure persists past six months; b) Individualized Care, with regimen choice based on results of genotypic resistance tests and urine tenofovir assays; or c) Immediate Switch to PI-based second-line ART. The primary outcome will be viral suppression (<50 copies/mL) at 48 weeks post-enrollment using the FDA snapshot definition. We hypothesize that rates of viral suppression at 48 weeks will be higher in the Individualized Care arm than in the Maintenance on TLD and Immediate Switch arms.,
|
Uganda |
2023-02-09 11:06:56 |
2026-02-09 |
Medical and Health Sciences |
Clinical Trial |
Non-degree Award |
|
| View |
|
Sort By: |
|
|
|
| |
|